New treatment modalities for basal cell carcinoma

Area of Science:

• Dermatology
• Oncology

Background:

• Basal cell carcinoma (BCC) is a prevalent nonmelanoma skin cancer (NMSC) linked to childhood sun overexposure.
• UV-induced mutations in tumor suppressor genes (PTC, p53) and gene polymorphisms (MC1R, XPD) are associated with BCC.
• While BCC mortality is low, rising incidence and morbidity create a significant economic burden.

Purpose of the Study:

• To review current and emerging treatment modalities for basal cell carcinoma (BCC).
• To highlight the importance of early recognition and effective management strategies for BCC.
• To discuss the economic implications of BCC incidence and treatment.

Main Methods:

• Review of established BCC treatments: excision, curettage, electrodessication, surgery, cryosurgery, and radiotherapy.
• Evaluation of pharmacologic treatments: 5-fluorouracil and intralesional/perilesional cytokines.
• Inclusion of novel therapeutic approaches: photodynamic therapy and imiquimod 5% cream.

Main Results:

• Traditional treatments remain standard for BCC management.
• Photodynamic therapy and imiquimod 5% cream demonstrate effectiveness in resolving BCC lesions.
• The review synthesizes a range of therapeutic options for BCC.

Conclusions:

• Early detection and appropriate treatment are vital for reducing BCC incidence and healthcare costs.
• Emerging therapies offer promising alternatives for BCC management.
• Comprehensive understanding of BCC treatments is essential for effective patient care.